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Efficacy and tolerability of STOPAIN for a migraine attack
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Objective:To determine whether topical menthol 6% gel will relieve a migraine attack.
Materials and Methods: A single-center, open-label pilot trial of 25 patients with at least
1 year of diagnosed episodic migraine and <15 headache days per month. Patients treated
one migraine attack with STOPAIN topical menthol 6% gel to skull base within 2 h of
headache onset. Headache pain severity was assessed prior to and after gel application.
Results: Thirty-two patients enrolled and 25 completed the study. Prior to treatment, 7
patients had mild pain, 13 moderate pain, and 5 severe pain.Two hours following gel appli-
cation, 7 (28%) patients had no pain, 7 (28%) mild pain, 6 (25%) moderate pain, and 5
(20%) severe pain. The majority of patients had similar pain intensity (8; 32%) or improve-
ment (13; 52%). At 24-h, only two non-rescued patients still had mild headache. Of the 25
completers, 2 patients took rescue medication prior to the 2-h period, and an additional 10
patients rescued between 2 and 24 h.
Conclusion: Study results showed a significant improvement in headache intensity by 2 h
after gel application. This pilot study shows STOPAIN gel may be effective in treating an
acute migraine attack.
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INTRODUCTION
Migraine is a common headache disorder with an estimated 1-year
prevalence of 36 million people (12% of the general population)
in the United States (1), where estimated annual costs total as
much as 17 billion dollars, including the direct costs of medica-
tions; office, clinic, or emergency department visits; laboratory
and diagnostic services; and management of treatment side effects.
Indirect costs from lost productivity in the workplace add substan-
tially to the total (2). According to the World Health Organization,
migraine is 19th cause of disability worldwide. Headache disor-
ders impose burdens that include substantial personal suffering,
impaired quality of life, and financial cost. Repeated headache
attacks, and often fear of future attacks, damage family life, social
life, and employment (3).
To date, formulations such as oral pill/powder, nasal spray, rec-
tal suppository, and injectable medication are available options
for acute migraine treatment. Topical treatments, in contrast, are
interesting alternatives due to their accessibility, low cost, rapid
onset of action, lack of systemic side effects, and the fact that they
bypass the gastrointestinal tract.
Menthol is a natural compound manufactured in many topical
medications. It has a number of potential peripheral and cen-
tral analgesic effects. When administered systemically, it blocks
voltage-gated calcium and sodium channels in superficial dor-
sal horn neurons, resulting in decreased neuronal excitability and
blocked spontaneous synaptic transmission (4). Topical menthol
blocks voltage-gated sodium channels in dorsal root ganglion neu-
rons (5) and desensitizes nociceptive C-fibers; the sensitization
of which is associated with cutaneous allodynia (6). The cooling
sensation of menthol has been attributed to activation of tran-
sient receptor potential melastatin eight ion channels (7), which
may be responsible for the analgesic effect (8). Thus, the molecular
mechanism of menthol analgesia includes both central and periph-
eral effects. Anecdotal evidence suggests that they are effective for
headache relief. Our study examined headache pain severity after
applying 6% menthol gel (STOPAIN) topically.
MATERIALS AND METHODS
STUDY DESIGN
We conducted a single-center, open-label pilot study that was
approved by Thomas Jefferson University Institutional Review
Board. Patients were recruited from outpatients who attended the
Jefferson Headache Center between June and August of 2012. The
study population consisted of 32 patients who had been diagnosed
for 1 year with episodic migraine with or without aura according
to the International Classification of Headache Disorders (2nd
Edition-2004). Eligible patients between 18 and 65 years of age at
screening were required to have 1–10 migraine attacks and no more
than 15 total headache days per month. Subjects who had a diag-
nosis of basilar or hemiplegic migraine were excluded. Additional
exclusion criteria included medical or psychiatric conditions that
would increase the risk of adverse events or interfere with study
assessments, participation in an investigational drug trial in the
30 days prior to the screening visit, and pregnancy or lactation.
Women of childbearing potential were required to use effective
contraception during participation.
Participants provided written informed consent prior to under-
going screening procedures. The screening visit (Visit 1) included
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a review of the patient’s medical and headache history and cur-
rent medications. Vital signs and a urine pregnancy test were
required for women of childbearing potential. Subjects were asked
to treat a single migraine attack within 8 weeks of Visit 1. They
were instructed to apply two pumps of the treatment gel from the
metered dosing bottle to the area below and abutting the base of
the skull to the base of the neck as well as behind and between the
ears within 2 h of the onset of a migraine attack. If they had no
relief after 2 h of gel application, they were permitted to use rescue
medication.
Subjects were provided with a take-home diary. Within 1 h of
headache onset, they were instructed to record pain severity (mild,
moderate, or severe) and associated symptoms before applying the
study gel, and at multiple time points (30, 60, and 90 min and 2,
4, and 24 h) after administering the gel. They also recorded the
presence or absence of photophobia, phonophobia, nausea, and
vomiting. Adverse events and rescue medications, including the
time of treatment and dose, were to be recorded.
After treating the migraine attack and completing the diary,
subjects were asked to return to Jefferson Headache Center for
a final visit (Visit 2) or to return the diary and other study sup-
plies by mail (shipping materials were offered to each participant).
During the final visit, the study drug and diary were collected and
reviewed, and any changes in concomitant medications and/or
medical conditions since the screening visit were recorded.
STUDY TREATMENT GEL
Active ingredients: Mentholum (l-menthol), Belladonna 3×
HPUS, Nux Vomica 6× HPUS, Iris Versicolor 6× HPUS, and
Sanguinaria canadensis 6× HPUS. Inactive ingredients: water
(USP), ethanol (USP), cambopol polymer, propylene diglycol, and
triethanolamine.
OUTCOME MEASURES AND STATISTICAL ANALYSIS
The primary objective is to observe the responses after topical gel
application in order to determine whether larger, well-controlled
trials are warranted. The primary endpoint is the headache inten-
sity reduction 2 h after treatment. An exploratory endpoint is the
headache intensity reduction at 24 h after treatment. For statistical
analysis, ordinal conversion of pain levels were assigned as 0= no
pain, 1=mild pain, 2=moderate pain, and 3= severe pain. The
Wilcoxon sign-rank test was used to compare pre-treatment pain
severity with pain severity 2 h after gel application, as well as to
compare pre-treatment pain severity with pain severity 24 h after
gel application.
RESULTS
Thirty-two subjects with episodic migraine met the inclusion cri-
teria and were enrolled in the pilot study. Of these, 25 subjects
completed the study and seven were lost to follow up. Of the 25
completed subjects, 7 had mild pain, 13 had moderate pain, and
5 had severe pain before the topical treatment. Figure 1 illustrates
the progression of headache intensity throughout the study period.
Two hours after gel application, 7 subjects had no pain, 7 mild pain,
6 moderate pain, and 5 severe pain. Two completers rescued with
medication due to progression from moderate to severe pain and
were pain free afterwards. Twelve of the 23 non-rescue subjects
FIGURE 1 | Progression of reported headache intensity on four-point
scale (0=none, 1=mild, 2=moderate, 3= severe) throughout the
study period. Rescued subjects (patterned) and non-rescued subjects (gray
scale) were grouped separately. Total number of patients in this study
was 25.
FIGURE 2 | Average (mean±1SD) headache severity on four-point
scale at before treatment, 2 h post treatment, and 24h post treatment
(all 25 completers). Wilcoxon sign-rank tests show significant reductions
in pain intensity at both 2 h (p=0.029) and 24 h (p<0.001).
(52%) reported improvement in headache pain by at least 1 sever-
ity level (e.g., from severe to moderate), 8 (35%) similar severity
level, and 3 (13%) worse pain. Improvements were reported in
3 (43%), 7 (54%), 3 (60%) of mild, moderate, severe groups,
respectively. After 24 h, 13 non-rescued subjects (11 pain free, 2
mild pain) showed pain improvement without any medication.
Ten additional subjects reported the use of medication. The over-
all rates of rescue medication use are 3 (43%), 7 (46%), 3 (60%) for
mild, moderate, severe groups, respectively. The total 12 rescued
subjects were pain free except 1 having worsening moderate pain.
Using ordinal conversion of headache severity, the mean
headache severity levels are at pre-treatment= 1.92 (close to mod-
erate pain), at 2 h= 1.36 (between mild and moderate pain), and
at 24 h= 0.16 (very mild pain) (Figure 2). Wilcoxon sign-rank
test shows that a topical application of the study gel is signifi-
cantly associated with a reduction in migraine severity after 2 h
(Z =−2.18, p= 0.029) and after 24 h (Z =−4.342, p< 0.001).
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FIGURE 3 | Progression of average headache reported from subjects
with (inverted open triangle) and without (open triangle) rescue
medication use. The pain progression of both non-rescued and overall
subjects (solid circle) is nearly identical.
Figure 3 illustrates the overall progression of average pain inten-
sity, as well as the rescued and non-rescued subjects, throughout
the study period. Statistically, analysis on non-rescue subjects
showed similar findings as overall subjects (data not shown).
Fifteen of the 25 subjects provided feedback regarding using
one’s fingers to apply the gel. Twelve participants had no prob-
lems with the method of application and found the gel easy to use.
Three participants said that they found the method acceptable,
but complained that the gel could be messy, hard to pump, and
difficult to apply if one had thick hair. Three participants said that
the recommended method of application would not deter them
from repeat use despite their complaints. One of the three partic-
ipants with complaints said that a roll-on would be preferable to
applying the gel with one’s fingers.
DISCUSSION
Given its unique properties, topical treatments for migraine
headache may provide an alternative for episodic migraine suf-
ferers. This open-label pilot study showed a statistically significant
improvement in headache by at least one severity level in 52% of
subjects 2 h after applying menthol 6% gel. Two-hour headache-
free rate was 28%. Only 2 subjects (8%) required rescue med-
ication before 2 h. This shows a potential pain-relieving property
from topical menthol application. Interestingly, subjects with pre-
treatment severe headache have higher rate of pain improvement
after 2 h and also reported higher rate of rescue medication use
within 24 h. Single application of menthol 6% gel is probably more
useful for short-term ablation in migraine patients. After 24 h,
most subjects, rescued or non-rescued, showed headache improve-
ment, which could be attributed to the natural progression of the
migraine.
Limitations of this study include the small sample size and
open-label, non-placebo-controlled design. In previous studies
conducted in 2010 by Borhani Haghighi et al., a 10% menthol
solution applied to the forehead and temporal area showed sig-
nificant improvement in headache pain and associated symptoms
at 2 h compared to placebo in patients with episodic migraine
without aura (9). Our findings of significant improvement after
6% menthol gel use provide a basis for further placebo-controlled
studies of topical menthol treatment.
This open-label pilot study demonstrates that STOPAIN 6%
menthol gel is safe and may be effective in the treatment of an
acute migraine attack. Because of the limitations of this study, a
larger placebo-controlled clinical trial is warranted.
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